Skip to content

Site logo

Main menu
  • Company
    • Company overview
    • Stories
    • History
    • Environmental, Social & Governance (ESG)
      • ESG overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact investing
      • Transparency disclosures
      • ESG resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct & compliance
    • Diversity & inclusion
    • Policies & positions
    • Business development & licensing
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
    • Pipeline
    • Discovery & development
    • R&D locations
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
  • Products
    • Products list
    • Safety data sheets
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Patient resources
    • Patient & treatment education
  • Careers
    • Careers
    • Search jobs
    • Our divisions
      • Research & development
      • Manufacturing & supply
      • Human Health
      • Animal Health
      • Global support functions
    • Veterans
    • Student opportunities
    • Compensation & benefits
    • How we hire
    • MSD Careers
    • Events
    • Talent community
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
      • Investor resources overview
      • Organon resources
      • Request for information
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
two scientists wearing masks

Our COVID-19 efforts

Learn more
Contact us

Worldwide Countries outside of the United States and Canada.

What can we help you find?

Search for:
Environmental, Social & Governance

3 ways to advance cancer health care equity

Mary-Ann Etiebet, AVP of corporate responsibility, explains why inequity in cancer care is an urgent global health challenge

January 21, 2022

Share this article

Female patient and doctor

Everyone deserves an equal opportunity to achieve their full health potential, and that includes access to cancer care. Cancer health care equity is an urgent global health and societal issue, and thankfully, the health care community is coming together to address cancer care disparities.

Mary-Ann Etiebet
Mary-Ann Etiebet, AVP of corporate responsibility

In November, I was honored to join several experts in an inspiring panel on health care disparities in oncology as part of the Merck Patient Advocacy Connection (MPAC) briefings organized by the Patient Advocacy Team. This year’s virtual panel, emceed by my colleague Hilary Hansen, included Beth Battaglino and Rebecca Sager from HealthyWomen, Sally Werner from Cancer Support Community, and Victoria Wolodzko from Susan G. Komen.

I learned from the experts about several issues that can create disparities in cancer care among certain populations and the innovative ways their organizations address these challenges.

Here are three actions MPAC panelists identified as critical to closing the cancer care equity gap.

01.

Addressing financial burdens of care

HealthyWomen’s Battaglino and Sager explained how the financial burden of cancer care disproportionately affects women, people of color and low-income earners. The cost and time away from work often mean that these groups must choose between personal sacrifice or skipping preventive care and treatment in order to make ends meet. Innovations such as in-home cervical cancer tests can help to overcome the challenges of scheduling and paying for appointments. Providing financial counseling as a component of care can also help alleviate some of the additional stress incurred by these populations.

02.

Understanding cultural considerations

Wolodzko discussed learning through focus groups with Black breast cancer patients that there was widespread distrust of medical providers. However, this was mitigated if the provider was also from the Black community. To address this, Susan G. Komen is seeking to increase diversity in the health care workforce through a training program specifically for Black patient navigators.

03.

Meeting patients where they are

Closing the health equity gap means meeting patients where they are – sometimes literally. Werner shared how rural populations must often travel hundreds of miles in order to seek care. The burden of this travel can significantly impact outcomes. She highlighted how prior to 2018, there were no cancer care providers in the Navajo Nation. Thanks to the 2019 launch of the Tuba City Regional Health Care Corporation’s new cancer center — the first cancer treatment center on a U.S. reservation — there are now two oncologists available to test and care for patients, resulting in a noticeable increase of visits, repeat visits and treatments for a population that has been disproportionately affected. Meanwhile, Cancer Support Community partners with the cancer center to provide resources and patient and caregiver support on site. The passage of the Bipartisan Infrastructure Deal may allow for even greater access and continued building of telehealth services to bring more care to remote places.

We are dedicated to health equity in cancer care. We will continue to engage with the entire cancer community, including health care professionals, patients, advocacy groups and policymakers to inform our efforts.

Discover more stories

Pride, pediatrics and parenting

New podcast: Meet the dealmakers 

Safeguarding the environment through green chemistry

View all stories

Explore more in

Clinical trials
Oncology
Patients and caregivers

Related links

related content image #1

Environmental, Social & Governance (ESG)

Supporting society, people and communities around the world is fundamental to our long-term success

related content image #2

Oncology

Our mission is to deliver innovations that extend and improve lives of people with cancer

related content image #3

Patients & caregivers

Your well-being is our purpose

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Environmental, Social & Governance (ESG) Report
    Reporting on our commitment to operating responsibly to benefit society
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life
  • Merck Animal Health
    The global animal health business unit of Merck
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue